

# Down's Syndrome And COVID-19: Risk Or Protection Factor Against Infection? A Molecular And Genetic Approach

M Altable, J de la Serna

---

## Citation

M Altable, J de la Serna. *Down's Syndrome And COVID-19: Risk Or Protection Factor Against Infection? A Molecular And Genetic Approach*. The Internet Journal of Neurology. 2021 Volume 22 Number 1.

DOI: [10.5580/IJN.55307](https://doi.org/10.5580/IJN.55307)

## Abstract

Down syndrome (DS) is the most common genetic cause of learning difficulties and intellectual disabilities. DS patients often present with several congenital defects and chronic diseases, including immunity disorders. Elevated levels of pro-inflammatory cytokines such as interleukin (IL) -6 and tumor necrosis factor alpha (TNF- $\alpha$ ) have been seen, which appear to vary with age. At birth, patients present with combined immunodeficiency, with frequent infections that decrease with age. Furthermore, high levels of IL-4 and IL-10 with anti-inflammatory properties and low levels of IL-6 and TNF- $\alpha$  are described in children. The immune system is believed to play or play an essential role in SARS-CoV-2 pathogenesis, and it has been associated with elevated levels of pro-inflammatory cytokines and an exaggerated cytokine release syndrome (CRS) that may eventually trigger a severe situation called cytokine storm. On the other hand, genetic features seem to be involved in the predisposition to illness and its severity. Overexpression of DSCR1 and ZAKI-4 inhibits the translocation of activated T-lymphocyte nuclear factor (NF-AT) to the nucleus, a main step in the inflammatory responsiveness. We discuss here, the possible role of immunology and genetic features of DS in the infection and prognosis in COVID-19.

## INTRODUCTION

More than one-third of COVID-19 patients present neurological symptoms during the course of the disease. Even in some patients, neurologic symptoms may be the initial or only presentations of the COVID-19.[1].

Down syndrome (DS), initially described by John Langdon Down in 1866 [2], is the most frequent aneuploidy characterized by a genetic disorder that results from the triplication of human chromosome 21 [3,4]; also related to chromosomal abnormalities such as translocation and in mosaicism [4,5]. There are three main types of DS: trisomy 21 (most common form, all cells have a triple copy of 21st chromosome), mosaicism (some cells have three copies of chromosome 21 and some cells have two copies of chromosome 21) and translocation (a third copy of chromosome 21 is translocated to another acrocentric chromosome). It is also the most common genetic cause of learning difficulties and intellectual disabilities [3]. The incidence in Europe is about 1,1 per 1000 live births [6] and in the United States about 1,42 in 1000 live births [7]; calculating that in the world there are around 6 million

people affected [8]. The survival of individuals with Down syndrome has increased in recent decades (owing mainly to improved management of congenital heart defects), resulting in large numbers of adults with DS.

DS is characterized by developmental delay, with typical dysmorphic characteristics and mild intellectual involvement [9], showing CI punctuations between 37 and 70 with an average of 50, while in the general population it ranges from 85 to 115 with a average of 100 CI [10].

Many conditions can occur in DS, such as congenital heart problems present in 50% of cases [11]; gastrointestinal problems [12]; and hypothyroidism [13]. It should also be noted that in DS immune system is usually compromised, which makes this population more exposed to infections, autoimmune conditions such as celiac disease, thyroid disease, or type I diabetes mellitus, in addition to autoinflammatory conditions [14]. DS is also related to eating problems with overweight, obesity, hypercholesterolemia and vitamin and mineral deficiencies [15].

Concerning neuronal aspects, there are generalized alterations in neurogenesis, an excessive number of astrocytes, dendritic atrophy and problems in establishing new neuronal connections [16]. It has also been related to a smaller brain volume, maturation disorders, reduced neurotransmitter release, The lower brain volume is related to psychomotor impairment, which affects cognition, gait quality, and voluntary movement [17]. Moreover, hypoplasia, that mainly affects the cerebellum, in addition produces speech balance and coordination problems [18].

Regarding to neurodegenerative processes, DS is associated with the presence of early Alzheimer's, between the age of 40 to 50 years [19]. DS dementia is the most common form of dementia in individuals under 50 years of age [20]. However, the causes of this early deterioration are currently under discussion, being attributed to neuronal changes associated with insulin levels [21], which plays a neuroprotective role against ischemia, oxidative stress, apoptosis and toxicity of amyloid- $\beta$  (A $\beta$ ) [22]. Besides, the association between Alzheimer's disease (AD) and DS has been described, together with high levels of tumor necrosis factor alpha (TNF- $\alpha$ ) and interleukin (IL)-6, which are pro-inflammatory cytokines [23,24]. Parkinson's and Huntington diseases have also been correlated with DS [3]. Down Syndrome (DS), is also characterized by over-expression of the APP and DYRK1A genes, located on the triplicated chromosome 21. This chromosomal abnormality leads to a cognitive decline mediated by Amyloid- $\beta$  (A $\beta$ ) overproduction and tau hyper-phosphorylation as early as the age of 40, and it has speculated DS individuals may benefit from active immunotherapy against A $\beta$  from a young age [25].

In February 2020, the World Health Organization named COVID-19 disease, which means coronavirus disease 2019 [26]. The virus that causes COVID-19 is called SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus); previously, it was called 2019-nCoV [27,28]. The World Health Organization (WHO) announced the new disease's official name as "coronavirus disease 2019" (COVID-19) and the International Committee on Virus Taxonomy named it SARS-CoV-2. On March 11, 2020, the WHO declared the pandemic [26]. Since the start of the pandemic until July 14, 2020, more than thirteen million cases have been reported worldwide [29]. Currently, its genomic sequence has already been made public (Wuhan-Hu-1, GenBank Accession No. MN908947). However, the pathogenic mechanisms and the

genetic role in them are not yet fully understood.

## **IMMUNOLOGY**

SARS-CoV-2 infection activates the innate immune system, generating an excessive response that could be related to more significant lung injury. Pro-inflammatory cytokines (IL-2R, IL-6, IL8, IL10, and TNF $\alpha$ ) has been also found to be associated to a hypercoagulability state [30] leading to the development of vascular disorders such as hearth [31] and cerebrovascular diseases [32], and worse clinical evolution. Clinical observations suggest that when the immune response is unable to effectively control the virus, as in older people with a weakened immune system, the virus would spread more efficiently, causing lung tissue damage, which would activate macrophages and granulocytes and could lead to the massive release of proinflammatory cytokines [33].

A Chinese research team has described the activation circuit of this immune pathway from the activation of aberrant CD4 + and CD8 + T helper (Th) lymphocytes (with higher expression of inflammatory markers, compared to healthy controls). In patients with SARS-CoV-2 pneumonia admitted to the intensive care unit (ICU) compared to those not admitted to the ICU, and with healthy controls, they observed a correlation with a higher proportion of CD4 + T cells that produce IL-6 and GM-CSF (granulocyte-macrophage colony-stimulating factor) with the severity of COVID-19 cases [34]. Other studies have observed the presence of elevated levels of IL-6 and other proinflammatory cytokines in patients with severe COVID-19 [35]. This activation could carrying cytokine release syndrome (CRS), which can trigger a positive feedback loop that overwhelms counter-regulatory homeostatic mechanisms and results in a cytokine storm [36] (Figure 1). It would be associated with acute respiratory failure syndrome or adult respiratory distress syndrome (ARDS), which has been described as the main cause of death from COVID-19 [37]. CRS occurs when large numbers of leukocytes (neutrophils, macrophages, and mast cells) are activated and release large amounts of proinflammatory cytokines [38].



IFN signalling in DS [48]. Previous epidemics of coronavirus (SARS) and influenza (bird flu and Spanish flu) produced a high number of deaths. The cytokine storm is believed to be the cause. Preliminary studies conducted in Hong Kong [50] indicated that this was probably the leading cause of death during the 2003 SARS epidemic, as was the 2019-2020 coronavirus (SARS-CoV-2) [53].

## **GENETICS**

Solid malignancies (apart from testicular cancer) are less common, resulting in a lower overall risk for malignancies in Down syndrome [51,54,55]. Overexpression of DSCR1 and ZAK1-4 inhibits the transcription of calcineurin-dependent genes, by inhibiting the translocation of activated T-lymphocyte nuclear factor (NF-AT) to the nucleus [56]. Precisely the non-structural protein SARS-CoV 1 (Nsp1) induces the expression of IL-2 through the activation of NF-AT [57,58] which could trigger the cytokine storm observed in patients. Therefore, over-activation of the DSCR1 protein, in addition to protecting against cancer, might be expected to do so in the effects of COVID-19. Prefferle et al. identified redundant interactions between SARS-CoV non-structural protein Nsp1 and a group of host proteins with peptidyl-prolyl cis-trans-isomerase activity, including the cyclophilins/immunophilins PPIA, PPIG, PPIH and FKBP1A, FKBP1B [58]. These modulate the Calcineurin/NFAT pathway that plays an important role in immune cell activation [59,60]. They showed that SARS-CoV non-structural protein Nsp1, as well as full replicating SARS-CoV, enhance the CnA/NFAT pathway and induce NFAT-responsive promoters. This point could be a target for ciclosporina A in treatment of the infection [58]. Like DSCR1 it inhibits this pathway in BS.

In addition, increased neuroinflammation in DS brains appears to be mainly mediated by the exacerbation of macrophage activation state 1 (M1) cells due to the triplication of some critical inflammatory-associated genes, including RCAN1, CXADR, ADAMTS1, ADAMTS5, TIAM1, and IFNGR2 [41].

The SARS-CoV-2 genome is made up of a single positively polarized single-stranded RNA chain (+ ssRNA) of approximately 30,000 base pairs. This RNA chain structurally resembles a messenger RNA (mRNA) of eukaryotic cells. However, unlike eukaryotic mRNAs, this viral genome contains at least six open reading frames (ORFs) [61–63]. Thus, the first two thirds (closer to the 5' end) code for the viral replicating gene. This gene is made

up of two ORFs (ORF 1a and ORF 1b) [61], which, at the beginning of the infection, will be directly translated into two large polyproteins called pp1a and pp1ab. These polyproteins will subsequently be proteolytically processed to generate 16 non-structural proteins (nsps), which will be involved in the replication of the viral genome and the transcription of subgenomic mRNAs (sgRNAs) [64–67].

## **CONCLUSION**

Even though the effects of DSCR1 overexpression are contradicted by the increase in IL-2 levels in DS and the probability of an exacerbated immune response, it could be explained by the differences between the infant and adult stages. That is, in children, there would be an immunodeficiency as already described in the last decades, that would facilitate infections; with decreased levels of pro-inflammatory interleukins such as IL-2. However, in adults, there would be a pro-inflammatory state with elevated pro-inflammatory cytokines levels, such as IL-2, IL-6 and TNF- $\beta$ , as described in DS (also related to AD).

According to this hypothesis, DS could be a risk factor for COVID-19 in the child, while in adulthood, it would protect against SARS-CoV-19 infection, but with a worse prognosis due to an exaggerated immune response (cytokine storm).

Although DS cases have already been described with COVID-19, finding that on average they are admitted up to ten years younger than the general population, and with greater severity of symptoms [68], this does not allow us to conclude that it is a risk factor, but those who have been hospitalized showed more severe symptoms, without knowing their clinical history.

Therefore, with all the aforementioned, COVID-19 would not only affect depending on the person's state of health or age but could also be affected by genetic components such as the alteration of chromosome 21 present in Down syndrome.

On the other hand, it must be taken into account that despite the considerable increase in life expectancy in the case of SD [6], one of the characteristics of this group is accelerated and premature aging [69], so if we were to attend to the age of the organism, people over 40 would be in the highest risk group, as are those over sixty in the general population.

We believe that more properly designed studies are needed to understand a possible relationship between DS and COVID-19, based on these initial data.

## References

- [1] Niazkar, H.R., Zibae, B., Nasimi, A. et al. The neurological manifestations of COVID-19: a review article. *Neurol Sci* 41, 1667–1671 (2020). <https://doi.org/10.1007/s10072-020-04486-3>
- [2] Langdon-Down JLH. On some of the mental affections of childhood and youth being The Lettsomian Lectures delivered before The Medical Society of London in 1887 together with other papers. *Ment Affect Child Youth Being Lettsomian Lect Deliv before Med Soc London 1887 Together with Other Pap* 1990:1–84.
- [3] Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down's syndrome. *Lancet Neurol* 2016;15:622–36. [https://doi.org/10.1016/S1474-4422\(16\)00063-6](https://doi.org/10.1016/S1474-4422(16)00063-6).
- [4] Moreira L, El-Hani CN, Gusmão FAF. A síndrome de Down e sua patogênese: considerações sobre o determinismo genético. *Brazilian J Psychiatry* 2000;22:96–9.
- [5] Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. *Ment Retard Dev Disabil Res Rev* 2000;6:84–95.
- [6] Loane M, Morris JK, Addor MC, Arriola L, Budd J, Doray B, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: Impact of maternal age and prenatal screening. *Eur J Hum Genet* 2013;21:27–33. <https://doi.org/10.1038/ejhg.2012.94>.
- [7] Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL, et al. Current estimate of Down syndrome population prevalence in the United States. *J Pediatr* 2013;163:1163–8.
- [8] FAQ and Facts about Down Syndrome - Global Down Syndrome Foundation n.d. <https://www.globaldownsyndrome.org/about-down-syndrome/facts-about-down-syndrome/> (accessed 12 July 2020).
- [9] Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. *Lancet Neurol* 2010;9:623–33. [https://doi.org/10.1016/S1474-4422\(10\)70112-5](https://doi.org/10.1016/S1474-4422(10)70112-5).
- [10] Vicari S, Marotta L, Carlesimo GA. Verbal short-term memory in Down's syndrome: An articulatory loop deficit? *J Intellect Disabil Res* 2004;48:80–92. <https://doi.org/10.1111/j.1365-2788.2004.00478.x>.
- [11] Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. 'down syndrome: An insight of the disease'. *J Biomed Sci* 2015;22. <https://doi.org/10.1186/s12929-015-0138-y>.
- [12] Holmes G. Gastrointestinal disorders in Down syndrome. *Gastroenterol Hepatol from Bed to Bench* 2014;7:6.
- [13] Amr NH. Thyroid disorders in subjects with down syndrome: An update. *Acta Biomed* 2018;89:132–9. <https://doi.org/10.23750/abm.v89i1.7120>.
- [14] Verstegen RHJ, Chang KJJ, Kusters MAA. Clinical implications of immune-mediated diseases in children with Down syndrome. *Pediatr Allergy Immunol* 2020;31:117–23. <https://doi.org/10.1111/pai.13133>.
- [15] Matuszak K, Bryl W, Pupek-Musialik D. Obesity in children and adolescents with mental retardation. *Forum Zab Metab.*, vol. 1, 2010, p. 55–63.
- [16] Bartesaghi R, Guide S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? *Rev Neurosci* 2011;22:419–55. <https://doi.org/10.1515/RNS.2011.037>.
- [17] Teipel SJ, Alexander GE, Schapiro MB, Möller H-J, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. *Brain* 2004;127:811–24.
- [18] Šveljo O, Čulić M, Koprivšek K, Lučić M. The functional neuroimaging evidence of cerebellar involvement in the simple cognitive task. *Brain Imaging Behav* 2014;8:480–6. <https://doi.org/10.1007/s11682-014-9290-3>.
- [19] Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VLJ, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. *Nat Rev Neurosci* 2015;16:564–74.
- [20] Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial. *Lancet* 2012;379:528–36. [https://doi.org/10.1016/S0140-6736\(11\)61676-0](https://doi.org/10.1016/S0140-6736(11)61676-0).
- [21] Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, et al. Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. *Neurobiol Dis* 2020;137. <https://doi.org/10.1016/j.nbd.2020.104772>.
- [22] Ferreira LSS, Fernandes CS, Vieira MNN, De Felice FG. Insulin resistance in Alzheimer's disease. *Front Neurosci* 2018;12:830.
- [23] Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A $\beta$  oligomers. *J Clin Invest* 2012;122:1339–53. <https://doi.org/10.1172/JCI57256>.
- [24] Lourenco M V., Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. TNF- $\alpha$  mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's  $\beta$ -amyloid oligomers in mice and monkeys. *Cell Metab* 2013;18:831–43. <https://doi.org/10.1016/j.cmet.2013.11.002>.
- [25] Illouz T, Madar R, Biragyn A, Okun E. Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model. *Brain Behav Immun* 2019;75:163–80. <https://doi.org/10.1016/j.bbi.2018.10.004>.
- [26] WHO | World Health Organization n.d. <https://www.who.int/> (accessed 13 July 2020).
- [27] Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *Int J Pept* 2012;2012.
- [28] Ministerio de Sanidad, Consumo y Bienestar Social - Profesionales - Información científico-técnica, enfermedad por coronavirus, COVID-19 n.d. <https://www.msbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/ITCoronavirus/home.htm> (accessed 13 July 2020).
- [29] Johns Hopkins CSSE. Coronavirus COVID-19 (2019-nCoV) 2020. <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6> (accessed 7 March 2020).
- [30] HORNSTEIN NL, Putnam FW. Clinical Phenomenology of Child and Adolescent Dissociative Disorders. *J Am Acad Child Adolesc Psychiatry* 1992;31:1077–85. <https://doi.org/10.1097/00004583-199211000-00013>.
- [31] Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH, et al. Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. *Can J Cardiol* 2020. <https://doi.org/10.1016/j.cjca.2020.05.018>.
- [32] Altable M, de la Serna JM. Cerebrovascular Disease in

- COVID-19: Is There a Higher Risk of Stroke? *Brain, Behav Immun - Heal* 2020;6:100092.  
<https://doi.org/10.1016/j.bbih.2020.100092>.
- [33] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;395:1033–4.  
[https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0).
- [34] Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. *BioRxiv* 2020:2020.02.12.945576.  
<https://doi.org/10.1101/2020.02.12.945576>.
- [35] Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents* 2020;34:1.
- [36] Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. *J Immunother Cancer* 2018;6:56.  
<https://doi.org/10.1186/s40425-018-0343-9>.
- [37] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.  
[https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- [38] Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014;124:188–95.  
<https://doi.org/10.1182/blood-2014-05-552729>.
- [39] Mei H, Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. *Zhonghua Xue Ye Xue Za Zhi* 2020;41:185–91.  
<https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0002>.
- [40] Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. *Int J Immunogenet* 2010;37:233–7.  
<https://doi.org/10.1111/j.1744-313X.2010.00914.x>.
- [41] Rueda N, Vidal V, García-Cerro S, Narcís JO, Llorens-Martín M, Corrales A, et al. Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. *Brain Behav Immun* 2018;73:235–51.  
<https://doi.org/10.1016/j.bbi.2018.05.008>.
- [42] Castro M, Crinò A, Papadatou B, Purpura M, Giannotti A, Ferretti F, et al. Down's syndrome and celiac disease: the prevalence of high IgA-antigliadin antibodies and HLA-DR and DQ antigens in trisomy 21. *J Pediatr Gastroenterol Nutr* 1993;16:265–8.
- [43] NESPOLI L, BURGIO GR, UGAZIO AG, MACCARIO R. Immunological features of Down's syndrome: a review. *J Intellect Disabil Res* 1993;37:543–51.  
<https://doi.org/10.1111/j.1365-2788.1993.tb00324.x>.
- [44] Scotese I, Gaetaniello L, Matarese G, Lecora M, Racioppi L, Pignata C. T cell activation deficiency associated with an aberrant pattern of protein tyrosine phosphorylation after CD3 perturbation in Down's syndrome. *Pediatr Res* 1998;44:252–8.  
<https://doi.org/10.1203/00006450-199808000-00019>.
- [45] Beckhaus AA, Castro-Rodriguez JA. Down syndrome and the risk of severe RSV infection: A meta-Analysis. *Pediatrics* 2018;142.  
<https://doi.org/10.1542/peds.2018-0225>.
- [46] Pérez-Padilla R, Fernández R, García-Sancho C, Franco-Marina F, Aburto O, López-Gatell H, et al. Pandemic (H1N1) 2009 Virus and Down syndrome patients. *Emerg Infect Dis* 2010;16:1312–4.  
<https://doi.org/10.3201/eid1608.091931>.
- [47] Krishnan US, Krishnan SS, Jain S, Chavolla-Calderon MB, Lewis M, Chung WK, et al. SARS-CoV-2 Infection in Patients with Down Syndrome, Congenital Heart Disease, and Pulmonary Hypertension: Is Down Syndrome a Risk Factor? *J Pediatr* 2020.  
<https://doi.org/10.1016/j.jpeds.2020.06.076>.
- [48] Espinosa JM. Down Syndrome and COVID-19: A Perfect Storm? *Cell Reports Med* 2020;1:100019.  
<https://doi.org/10.1016/j.xcrm.2020.100019>.
- [49] De Weerd NA, Nguyen T. The interferons and their receptors-distribution and regulation. *Immunol Cell Biol* 2012;90:483–91.  
<https://doi.org/10.1038/icb.2012.9>.
- [50] Duan ZP, Chen Y, Zhang J, Zhao J, Lang ZW, Meng FK, et al. Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome. *Zhonghua Gan Zang Bing Za Zhi= Zhonghua Ganzangbing Zazhi= Chinese J Hepatol* 2003;11:493.
- [51] Versteegen RHJ, Kusters MAA. Inborn Errors of Adaptive Immunity in Down Syndrome. *J Clin Immunol* 2020.  
<https://doi.org/10.1007/s10875-020-00805-7>.
- [52] Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, et al. Trisomy 21 consistently activates the interferon response. *Elife* 2016;5.  
<https://doi.org/10.7554/eLife.16220>.
- [53] Cytokine Storm and the H5N1 Influenza Pandemic: The Bird Flu n.d. <http://www.cytokinestorm.com/> (accessed 13 July 2020).
- [54] Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. *Genet Med* 2016;18:1151–7.  
<https://doi.org/10.1038/gim.2016.23>.
- [55] Satgé D, Seidel MG. The pattern of malignancies in down syndrome and its potential context with the immune system. *Front Immunol* 2018;9.  
<https://doi.org/10.3389/fimmu.2018.03058>.
- [56] Strippoli P, Lenzi L, Petrini M, Carinci P, Zannotti M. A new gene family including DSCR1 (Down syndrome candidate region 1) and ZAKI-4: Characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2). *Genomics* 2000;64:252–63.  
<https://doi.org/10.1006/geno.2000.6127>.
- [57] Liddicoat AM, Lavelle EC. Modulation of innate immunity by cyclosporine A. *Biochem Pharmacol* 2019;163:472–80.  
<https://doi.org/10.1016/j.bcp.2019.03.022>.
- [58] Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, et al. The SARS-Coronavirus-host interactome: Identification of cyclophilins as target for pan-Coronavirus inhibitors. *PLoS Pathog* 2011;7.  
<https://doi.org/10.1371/journal.ppat.1002331>.
- [59] Feske S, Giltman J, Dolmetsch R, Staudt LM, Rao A. Gene regulation mediated by calcium signals in T lymphocytes. *Nat Immunol* 2001;2:316–24.  
<https://doi.org/10.1038/86318>.
- [60] Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes Dev* 2003;17:2205–32.  
<https://doi.org/10.1101/gad.1102703>.
- [61] Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *J Microbiol Immunol Infect* 2020.  
<https://doi.org/10.1016/j.jmii.2020.03.022>.
- [62] Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol* 2020;92:424–32.
- [63] Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-

CoV: a comparative overview. *Infez Med* 2020;28:174–84.  
[64] Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). *J Microbiol Biotechnol* 2020;30:313–24. <https://doi.org/10.4014/jmb.2003.03011>.  
[65] Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol* 2020;92:418–23. <https://doi.org/10.1002/jmv.25681>.  
[66] Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in

Iran: Comparison with SARS and MERS. *Rev Med Virol* 2020;30. <https://doi.org/10.1002/rmv.2107>.  
[67] Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: A brief perspective from the front line. *J Infect* 2020;80:373–7. <https://doi.org/10.1016/j.jinf.2020.02.010>.  
[68] Malle L, Gao C, Bouvier N, Percha B, Bogunovic D. COVID-19 Hospitalization is More Frequent and Severe in Down Syndrome. *MedRxiv* 2020.  
[69] Zigman WB. Atypical aging in down syndrome. *Dev Disabil Res Rev* 2013;18:51–67. <https://doi.org/10.1002/ddrr.1128>.

**Author Information**

**Marcos Altable, M.D.**

Private Practice of Neurology. Neuroceuta. (Virgen de Africa Clinic)  
Ceuta, Spain

**Juan Moisés de la Serna, Ph.D.**

Department of Education. International University of La Rioja (UNIR)  
Madrid, Spain